Study details
Enrolling now
Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers
City of Hope Medical Center
NCT IDNCT05204147ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
20
Study length
about 4.1 years
Ages
18+
Locations
1 site in CA
About this study
This trial is testing the safety, side effects, and best dose of Ac225-DOTA-M5A in treating patients with advanced cancer. Ac225-DOTA-M5A is a radioactive antibody that targets CEA positive cancer cells to kill them.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Actinium Ac 225-DOTA-anti-CEA Monoclonal Antibody M5A
- 2.Undergo Biospecimen Collection
PhasePhase 1
Primary goalIncidence of adverse events
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Primary: Incidence of adverse events, Maximum tolerated dose (MTD)
Secondary: Best overall response, Overall survival, Progression-free survival
Procedures
diagnostic